DIABETES - DRUG APPROVED
Injectable Phase II
TrialWire™ Platform was engaged by the CRO.
We were involved from start-up and worked alongside the CRO and 16 sites in US, Australia, and New Zealand to deliver patients.
All patent engagement activity was via the Platform so patients could be quickly online screened and connected to their nearest site for follow-up.
In addition, we outreached to PAGs to leverage databases and websites to share the AI-Match screener link.
TrialWire™recruited 490 patients and the study was completed on time within budget.